One page, two pricing schemes
The plan table is the good part. It prints a three-month plan and a month-to-month plan for semaglutide with a per-month figure on each, and a month-to-month figure for tirzepatide, and it labels the cheaper one Best Value. That is a readable structure and it is what we have recorded.
Then the frequently-asked-questions block below it answers what is the cost of medication with a heading reading Flat Monthly Pricing and a sentence naming one program rate for semaglutide at all dose levels and another for tirzepatide at all dose levels. Neither figure appears anywhere in the table above. Both are lower than the table's month-to-month rates.
We are not resolving that. A seller stating two different prices for the same drug on one page has not made a mistake we can correct on its behalf; it has published a conflict, and the conflict is the fact. Our record carries the plan table, because those figures are attached to named plan lengths, and the FAQ figures are recorded in the row's own qualifier so the reader can see both.
The countdown timer
Above the table, a banner reads Spring Sale and runs a live countdown in days, hours, minutes and seconds. It was running on the sixth of September.
A sale named for a season that ended months ago, on a timer that never reaches zero, is a durability finding rather than a pricing one. It tells you the low figure is a marketing state rather than a rate. Seventy-eight of the one hundred and fifty-eight sellers here have a headline figure that is promotional, introductory, or conditioned on a commitment the number does not disclose, and this is one of them twice over.
What is disclosed, and what is not
The seller names its chief medical officer by name on the priced page, with a photograph and a quotation. Fifty of the one hundred and fifty-eight sellers here name an individual clinician at all, so this counts.
The operating company is self-identified in the opening sentence of the privacy policy, in the form of a legal name doing business as the brand. The two names share nothing, which is common and worth knowing: a reader searching for the brand will not find the company, and vice versa.
No compounding pharmacy is named. One hundred and twenty-six of the one hundred and fifty-eight sellers here name no compounding pharmacy. No service area is published; one hundred and fifteen of the one hundred and fifty-eight sellers here publish no service area at all.
On membership the site says no hidden fees and no surprise charges, which is a promise about the bill rather than an answer about a fee. Sixty-four of the one hundred and fifty-eight sellers here say nothing either way about a membership fee, and this is one of them.
The claim about dose
Both the table and the FAQ state that the price does not rise as the dose rises, in almost the same words: same price, every dose, and your price will never increase no matter what dose you are on. That is a real commitment and it is the one thing the two blocks agree about.
It matters more than it looks. A seller whose price steps up with the strength can quote a low entry figure and bill something else four months later, and several sellers on this roster do exactly that. This one says it will not. The problem is only that it says so twice, at two different prices.
Get Thin MD's published pricing
| Medication | Price | Verified |
|---|---|---|
| Semaglutide (compounded) | $169/moper month on the 3-month plan; the same page carries a countdown-timer Spring Sale banner reading as low as $119/mo, and its own pricing FAQ states a flat $119 program rate for all semaglutide doses | September 2026source |
| Semaglutide (compounded) | $199/moper month on the month-to-month plan, from the plan table on the priced page | September 2026source |
| Tirzepatide (compounded) | $299/moper month on the month-to-month plan; the same page FAQ states a flat $179 program rate for all tirzepatide doses | September 2026source |
compareglp may earn a commission when a reader signs up with a provider through a link on this site. 4 of the 158 providers reviewed here are paid partners today; the other 154 are not. See how this works.
See Get Thin MD's current price →Good fit if
- Readers who want a plan table with the term printed beside each figure rather than a single starting number.
- Buyers who want a written commitment that titrating up will not raise the bill.
- People who want to see a named chief medical officer rather than a reference to board-certified physicians.
- Anyone comparing a seller's marketing table against its own FAQ before deciding which number to believe.
Look elsewhere if
- Anyone who needs one price to mean one thing. The plan table and the pricing FAQ state different rates for both drugs on one page.
- Readers who want the compounding pharmacy named.
- Buyers who need to know whether the service reaches their state. No list is published.
- People who want the membership question answered rather than deflected into a promise about hidden fees.
- Anyone who reads a countdown timer as evidence that a price is about to rise.
How this review was verified
- Re-read the priced GLP-1 page and the privacy policy on 6 September 2026 rather than carrying any figure across from the research file that nominated this seller. That file recorded only the sale banner figure and none of the plan table.
- Compared the requested path to the effective path on every fetch and ran a nonsense path against the same host in the same run; it returned a not-found status.
- Extracted the page text from joined text nodes rather than from raw markup, so a figure split across elements is visible rather than invisible to a per-element pattern.
- Recorded both the plan table and the FAQ figures rather than choosing between them, and stored the plan table as the price rows because those figures carry a stated term.
- Read the operating company off the first sentence of the privacy policy in its own doing-business-as form.
- Screened the operating entity and the brand name against FDA's live warning-letter record with a known letter as a positive control and a nonsense string as a negative control in the same pass. Neither returned a letter. Untitled letters are published separately and were not searched, so this establishes no warning letter found rather than no FDA action.